Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Endocyte
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01684098CT.gov Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Testicular Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Etarfolatide (this asset) | Endocyte | P2 | B · 57 |
| Testosterone Undecylate | University Medical Center Groningen | P2/3 | BB |
| Fluorouracilum | National Cancer Institute (NCI) | P2 | B |
| Alvocidib | National Cancer Institute (NCI) | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | CCC |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Ludwig Institute for Cancer Research | P1/2 | CCC |
| Durvalumab | Ludwig Institute for Cancer Research | P1/2 | CCC |
| Guadecitabine | Nasser Hanna | P1 | CC |
| Tarlatamab | University of Arizona | P1/2 | CC |
+12 more in the Testicular Cancer cohort
Other indications for Etarfolatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P3 | B · 58 |
| Lung Adenocarcinoma | — | P2 | B · 57 |
| Ovarian Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Testosterone UndecylateUniversity Medical Center GroningenBB
- FluorouracilumNational Cancer Institute (NCI)B
- AlvocidibNational Cancer Institute (NCI)B
- OxaliplatinNational Cancer Institute (NCI)CCC
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerLudwig Institute for Cancer ResearchCCC
Citation
Floatz Terminal. Etarfolatide in Testicular Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/etarfolatide-testicular-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →